TRDA
Entrada Therapeutics Inc · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website entradatx.com
- Employees(FY) 150
- ISIN US29384C1080
Performance
+4.39%
1W
+17.85%
1M
+4.24%
3M
-2.47%
6M
-0.66%
YTD
+11.2%
1Y
Profile
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead therapeutic candidates, which include ENTR-601-44 and ENTR-601-45, which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701, which is in preclinical trail for the treatment of myotonic dystrophy type 1. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Investment Analysis Report: TRDA
Overview
TRDA is a company operating in the Health Technology sector, specifically in the Biotechnology industry. The company has a market capitalization of $479.83 million. In this report, we will conduct a comprehensive analysis of TRDA's financial health, earnings and revenue growth, profitability, operating m...
Technical Analysis of TRDA 2024-05-10
Overview:
In analyzing the technical indicators for TRDA over the last 5 days, we will delve into the trends, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions for informed decisi...
Recent News & Updates
- 2024-05-17 06:45
Daily – Vickers Top Buyers & Sellers for 05/17/2024(Argus Research)
- 2024-05-16 19:02
- 2024-05-16 16:35
- 2024-05-16 07:00
- 2024-05-15 19:00
- 2024-05-08 07:24
Entrada Therapeutics First Quarter 2024 Earnings: Beats Expectations(Simply Wall St.)
- 2024-05-07 07:00
- 2024-05-07 01:53
- 2024-05-06 19:00
- 2024-04-10 03:29
Insiders are Piling into These 5 Healthcare Stocks in 2024(Insidermonkey)
- 2024-04-04 02:00
- 2024-03-27 01:27
- 2024-03-19 06:28
- 2024-03-14 17:31
- 2024-03-13 07:00
- 2024-03-12 19:00
- 2024-02-07 07:00
- 2024-02-06 18:00
- 2024-01-28 19:14
- 2024-01-08 09:40
- 2024-01-04 10:40
- 2024-01-04 09:46
- 2024-01-03 10:52
- 2024-01-03 07:00
Entrada Therapeutics Promotes Nathan J. Dowden to President(GlobeNewswire)
- 2024-01-02 18:00
Entrada Therapeutics Promotes Nathan J. Dowden to President(globenewswire)
- 2023-12-29 09:48
- 2023-12-28 11:13
- 2023-12-28 11:07
- 2023-12-28 07:01
- 2023-12-26 11:32
Page 1 of 4
previousnext